Featured Press Releases

Mercury Bio

Mercury Bio's new project includes Los Alamos and the National Center for Genome Resources.

Eligo Bioscience Receives $5 Million to Accelerate Development of Its Breakthrough Immuno-Dermatology Gene Therapy Platform

Eligo Bioscience Receives $5 Million to Accelerate Development of Its Breakthrough Immuno-Dermatology Gene Therapy Platform

  • 13 May 2025

Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines,...

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

Galderma’s Relfydess™ (RelabotulinumtoxinA) receives positive decision for use in Europe

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

Blue Earth Therapeutics shares positive Phase 1 results for Lutetium (177Lu) rhPSMA-10.1 Injection, advancing its clinical development

IKA introduces new accessories for the HABITAT research bioreactor.

IKA introduces new accessories for the HABITAT research bioreactor.

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.